Vanguard Portfolio Management
ARCT icon

Vanguard Portfolio Management’s Arcturus Therapeutics ARCT Stock Holding History

Vanguard Portfolio Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.39M Sell
951,575
-26,347
-3% -$208K ﹤0.01% 2366
2026
Q1 		$7.55M Buy
+977,922
New +$7.14M ﹤0.01% 2199

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management's ARCT Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Arcturus Therapeutics (ARCT) stake by 2.7% in Q2 2026, selling an estimated $208K and leaving 951,575 shares worth $6.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2366.

Vanguard Portfolio Management first reported a position in ARCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.55M in Q1 2026. 125 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Vanguard Portfolio Management held 951,575 shares of Arcturus Therapeutics worth $6.39M as of Q2 2026.
  • Vanguard Portfolio Management sold 26,347 Arcturus Therapeutics shares in Q2 2026, an estimated $208K.
  • Arcturus Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2366 holding.
  • Vanguard Portfolio Management first reported a position in Arcturus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Arcturus Therapeutics position peaked at $7.55M in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.